7月6日，安进盘中下跌3.19%，报361.15美元/股，成交额1.13亿美元。
消息面上，生物科技板块当日整体走弱，行业主要个股普遍下跌。公司层面，欧洲药品管理局此前建议撤销安进旗下Tavneos在欧盟的上市许可，认为支持该药获批的关键研究未遵守良好临床实践标准，提交数据存在不准确及误导性问题。此外，Rothschild & Co Redburn虽将安进目标价从200美元上调至220美元，但该目标仍显著低于市场一致预期的355.78美元，反映出部分机构对公司前景的谨慎态度。
安进所在的生物科技行业中，福泰制药跌2.57%，吉利德科学跌2.51%，再生元制药公司跌2.0%，艾伯维公司跌1.97%，Moderna涨0.93%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.